HUE027953T2 - A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása - Google Patents
A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása Download PDFInfo
- Publication number
- HUE027953T2 HUE027953T2 HUE09777272A HUE09777272A HUE027953T2 HU E027953 T2 HUE027953 T2 HU E027953T2 HU E09777272 A HUE09777272 A HU E09777272A HU E09777272 A HUE09777272 A HU E09777272A HU E027953 T2 HUE027953 T2 HU E027953T2
- Authority
- HU
- Hungary
- Prior art keywords
- alpha
- cells
- heme
- haemoglobin
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
Claims (9)
- CLAIMS 1. 1, Alfa-i-míkrogíobulin oxidativ stresszel j<*r0 betegseg vagy állapot kezdésében vagy magdozésében történő oxidativ károseoasnafe enzimatikus redakcíé, |#.»^ÄiÄus redukció «s gyokrogás kom·» . .bid-ác^jávai történd '|á'«\ésévál vagy megelőzlek'' s felétdid, hogy az állapot vagy betegség wn praedámpsiá.
- 2. Álfa-'l-imikrogiobisllo az i, igénypont szeri nd aikaímazasra, ahol a betegség vagy álladót szabad dsmogíoblansk agy tasttoipdakbap cMshő jelenlétével függ össze.
- 3. Alfa-l-mikreglübullo az 1. vagy 2. igénygotk szőri ott alkalmazásra, mely legalább 6ö%~ban azonos; a búmén afa^-míkröglobtflion®! (L számú szekvencia)1.
- 4. Alfa-i-'mlikfogíobulin az előző igényponti bármelyike szerinti alkalmazásra, aho l az alta-i-mskrogiobullrs humán aitdre-mskroglöbulín (1. számú szekvencia).
- 5. AIM-1-mlkböpÄjifc az t-1, Igénypontok bármelyike szerint! alkalmazásra, áhöl az alfa-®$%~báh M&im& a búmén tekom-bináns alfa-t-rniikrogiobuiinnal (2, számú szekvendb),
- 6. Alfa -1. - m i k rog l o b u írn az if % S, Igénypontok bármelyike szerinti alk kaimazásra, ahoi az alfa·· 1 -mikrogiohulin humán rakomöináns alfa-!-Mikroglöbulln :(2. számé szekvencia;},
- 7. Aiap-nzikrogiobuko az 1-6. Igénypontok bármelyike szerinti ai-kaimazásra, ahol az aifa-l -mikrogiobukot pareoter#lsan adagoljuk.
- 8. Aifa-Z'-mikmglgfealjn az 7-6, Igénypontok bármelyike szerinti alkalmazásra, ahol az alp-l-mlkreglöádllbt. lokálisam például e§y testüregben vagy a bőrre adagoljuk.
- 9.. Álfa* l-mikroglobufio az előző igénypontok bármelyike szerinti alkalmazásra, ahol az alfa-l-mskroglobulint alfa* i-mikrcgíobullnt és egy gyógyszerészetHeg elfogadható adalékanyagot tartalmazó készítményként adagoltuk, iö. Alfa-l-mikrogfohulln a 9. igénypont szerinti alkalmazásra, ahol a gyógyászatiig elfogadható adalékanyag oldószerek, pH-beáüitó szerek, ozmózis* aktív szerek, koszol versek, szoiubilizáió szerek, emulgealószerek, szoszpendálószerek, felületaktív szerek, nedvesítoszerek, stb. közül választott.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13533808P | 2008-07-18 | 2008-07-18 | |
| DKPA200801024 | 2008-07-18 | ||
| US18938108P | 2008-08-18 | 2008-08-18 | |
| DKPA200801116 | 2008-08-18 | ||
| US19750608P | 2008-10-27 | 2008-10-27 | |
| DKPA200801478 | 2008-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE027953T2 true HUE027953T2 (hu) | 2017-01-30 |
Family
ID=41550762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE09777272A HUE027953T2 (hu) | 2008-07-18 | 2009-07-17 | A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása |
| HUE13172049A HUE030274T2 (hu) | 2008-07-18 | 2009-07-17 | A gyökmegkötõ és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13172049A HUE030274T2 (hu) | 2008-07-18 | 2009-07-17 | A gyökmegkötõ és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10350268B2 (hu) |
| EP (2) | EP2638915B1 (hu) |
| JP (3) | JP5694928B2 (hu) |
| AU (1) | AU2009270435B2 (hu) |
| CA (1) | CA2730531A1 (hu) |
| DK (2) | DK2313106T3 (hu) |
| ES (2) | ES2571956T3 (hu) |
| HR (2) | HRP20160760T1 (hu) |
| HU (2) | HUE027953T2 (hu) |
| PL (2) | PL2313106T3 (hu) |
| PT (1) | PT2638915T (hu) |
| WO (1) | WO2010006809A2 (hu) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5010920B2 (ja) | 2003-11-08 | 2012-08-29 | プロセラ・バイオロジクス | 治療に使用するためのヒト血漿由来のインターα阻害タンパク質の調製方法及びその組成物 |
| EA031877B1 (ru) | 2007-02-12 | 2019-03-29 | А1М Фарма Аб | Применение альфа-1-микроглобулина для профилактики или лечения преэклампсии |
| CA2726281C (en) | 2008-05-28 | 2023-04-18 | Prothera Biologics, Llc | Preparation and composition of inter-alpha inhibitor proteins from blood |
| MX357656B (es) * | 2012-09-05 | 2018-07-18 | A1M Pharma Ab | Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias. |
| WO2014039987A2 (en) * | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| EP3102224B1 (en) * | 2013-12-20 | 2019-02-20 | NephroGenesis, LLC. | Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis |
| MX2018011193A (es) * | 2016-03-18 | 2019-03-28 | A1M Pharma Ab | Proteinas derivadas de alfa-1-microglobulina novedosas y su uso. |
| WO2018094023A2 (en) * | 2016-11-16 | 2018-05-24 | Anand Prasad | Cyclic dipeptides and wound healing |
| JP2021501750A (ja) * | 2017-11-03 | 2021-01-21 | ガード セラピューティクス インターナショナル エービーＧｕａｒｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＡＢ | 骨髄細胞の保護のためのアルファ−１−ミクログロブリンの使用 |
| JP6906807B2 (ja) * | 2018-08-31 | 2021-07-21 | 一般社団法人クラインシュタイン医工学パースペクティブ | 透析装置 |
| WO2024165674A1 (en) | 2023-02-08 | 2024-08-15 | Guard Therapeutics International AB | Alpha-1-microglobulin derived peptide fragments and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166133A (en) | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
| US6103691A (en) * | 1994-03-23 | 2000-08-15 | Tschesche; Harald | Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins |
| US5910482A (en) | 1996-03-19 | 1999-06-08 | Board Of Regents, The University Of Texas System | Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor |
| JP2001348342A (ja) | 2001-04-12 | 2001-12-18 | Nippon Zoki Pharmaceut Co Ltd | 免疫調整・抗炎症剤 |
| DE10125883A1 (de) | 2001-05-28 | 2002-12-12 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie |
| DE10237423A1 (de) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| AR045074A1 (es) * | 2003-07-23 | 2005-10-12 | Applied Research Systems | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes |
| ITMI20032528A1 (it) | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US20060105419A1 (en) | 2004-08-16 | 2006-05-18 | Biosite, Inc. | Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions |
| JP2007001922A (ja) | 2005-06-23 | 2007-01-11 | Asahi Kasei Pharma Kk | 透析患者における腎疾患改善剤、又は機能性食品 |
| US20070292421A1 (en) | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
| US20080133141A1 (en) | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| EA031877B1 (ru) * | 2007-02-12 | 2019-03-29 | А1М Фарма Аб | Применение альфа-1-микроглобулина для профилактики или лечения преэклампсии |
-
2009
- 2009-07-17 ES ES09777272T patent/ES2571956T3/es active Active
- 2009-07-17 AU AU2009270435A patent/AU2009270435B2/en not_active Ceased
- 2009-07-17 EP EP13172049.2A patent/EP2638915B1/en not_active Not-in-force
- 2009-07-17 DK DK09777272.7T patent/DK2313106T3/en active
- 2009-07-17 US US13/054,188 patent/US10350268B2/en active Active
- 2009-07-17 PT PT131720492T patent/PT2638915T/pt unknown
- 2009-07-17 DK DK13172049.2T patent/DK2638915T3/en active
- 2009-07-17 HU HUE09777272A patent/HUE027953T2/hu unknown
- 2009-07-17 JP JP2011517819A patent/JP5694928B2/ja not_active Expired - Fee Related
- 2009-07-17 WO PCT/EP2009/005217 patent/WO2010006809A2/en active Application Filing
- 2009-07-17 HU HUE13172049A patent/HUE030274T2/hu unknown
- 2009-07-17 PL PL09777272T patent/PL2313106T3/pl unknown
- 2009-07-17 EP EP09777272.7A patent/EP2313106B1/en active Active
- 2009-07-17 ES ES13172049.2T patent/ES2614490T3/es active Active
- 2009-07-17 CA CA2730531A patent/CA2730531A1/en not_active Abandoned
- 2009-07-17 PL PL13172049T patent/PL2638915T3/pl unknown
-
2014
- 2014-11-21 JP JP2014236500A patent/JP6406987B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-10 JP JP2015241096A patent/JP6175478B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-29 HR HRP20160760TT patent/HRP20160760T1/hr unknown
- 2016-12-29 HR HRP20161808TT patent/HRP20161808T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015071620A (ja) | 2015-04-16 |
| HRP20161808T1 (hr) | 2017-02-24 |
| ES2614490T3 (es) | 2017-05-31 |
| PL2313106T3 (pl) | 2016-08-31 |
| JP6406987B2 (ja) | 2018-10-17 |
| JP6175478B2 (ja) | 2017-08-02 |
| DK2638915T3 (en) | 2017-01-30 |
| WO2010006809A3 (en) | 2010-05-27 |
| PT2638915T (pt) | 2017-01-10 |
| ES2571956T3 (es) | 2016-05-27 |
| JP2012505154A (ja) | 2012-03-01 |
| HRP20160760T1 (hr) | 2016-08-12 |
| CA2730531A1 (en) | 2010-01-21 |
| WO2010006809A2 (en) | 2010-01-21 |
| US20110190208A1 (en) | 2011-08-04 |
| HUE030274T2 (hu) | 2017-05-29 |
| AU2009270435A1 (en) | 2010-01-21 |
| JP5694928B2 (ja) | 2015-04-01 |
| JP2016102125A (ja) | 2016-06-02 |
| EP2638915B1 (en) | 2016-10-19 |
| EP2313106A2 (en) | 2011-04-27 |
| US10350268B2 (en) | 2019-07-16 |
| AU2009270435B2 (en) | 2014-10-16 |
| DK2313106T3 (en) | 2016-07-25 |
| PL2638915T3 (pl) | 2017-04-28 |
| EP2638915A1 (en) | 2013-09-18 |
| EP2313106B1 (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2313106T3 (en) | MEDICAL USE OF RADICAL binder and the antioxidant is alpha-1-microglobulin | |
| JP5685773B2 (ja) | 血管新生および創傷治癒活性がある薬剤 | |
| JP2018203756A (ja) | ミトコンドリア関連疾患の治療に使用するためのα−１−ミクログロブリン | |
| Ebaid et al. | Effect of STZ-induced diabetes on spleen of rats: improvement by camel whey proteins | |
| KR20090033329A (ko) | 가교된 헤모글로빈 혈액 대용품을 사용한 급성 혈액 손실 빈혈의 치료 방법 | |
| US20090291086A1 (en) | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia | |
| AU2014262273B2 (en) | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin | |
| JP2022533365A (ja) | 出血性脳卒中後の有害な二次神経学的転帰を処置する際に使用するためのハプトグロビン | |
| Sabapathy et al. | The Yin and Yang of alarmins in regulation of acute kidney injury | |
| CA2328134A1 (en) | The induction of antibiotic proteins and peptides by lait/scd14-protein | |
| CN105641688B (zh) | C1抑制剂在预防缺血-再灌注损伤中的应用 | |
| McCormick et al. | Clinically applicable thermal preconditioning attenuates leukocyte–endothelial interactions | |
| RU2405558C2 (ru) | Лекарственный препарат для лечения гипоксических и токсических митохондриальных нарушений и способ его получения | |
| US20130165391A1 (en) | B2-glycoprotein i peptide inhibitors | |
| Televiak et al. | Dynamic of indices of lipid peroxidation and antioxidant protection in muscular tissue and blood serum of rats with acute ischemia-reperfusion | |
| Li et al. | Kidney injury in a murine hemorrhagic shock/resuscitation model is alleviated by sulforaphane’s anti-inflammatory and antioxidant action | |
| CA2625888A1 (en) | Method of treating acute renal failure with thrombomodulin variant | |
| Dobryszycka | Haptoglobin in the new millenium | |
| JP3569904B2 (ja) | 臓器障害治療薬 | |
| WO2024023068A1 (en) | Use of an annelid molecule for treating and/or preventing at least one complement-activation associated disease | |
| Alotaibi et al. | Evaluation of the Healing Effect of Cordycepin and Melittin in Experimentally-Induced Wounds in Diabetic Rats | |
| JPH11349488A (ja) | クラスタリンを含有する免疫抑制剤 | |
| WO2014205077A1 (en) | Hemoglobin compositions |